Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center

Articles

Exploring Emerging Data in DLBCL

August 23rd 2021

A panel of experts in lymphoma reflect on major data that came out of the ASCO 2021 Virtual Meeting.

Looking at the Big Picture in DLBCL

August 23rd 2021

Key opinion leaders in lymphoma take a look at challenges in treating B-cell lymphoma and where they see the things moving in the future.

Treating Patients Post CAR T Therapy

August 23rd 2021

David Rizzieri, MD, discusses treatment approaches for after relapse on CAR T cell therapy or for patients who are ineligible for CAR T therapy.

Optimal Approaches to Bridging Therapy in DLBCL

August 16th 2021

Greg Nowakowski, MD, explains optimal approaches to bridging therapy before CAR T cell therapy in DLBCL.

Evaluating CAR T Therapies in Lymphoma

August 16th 2021

A panel of experts explain the differences among the multiple trial designs, patient populations, and CAR T constructs used for treatment of non-Hodgkin lymphoma.

Recommendations for CAR T-Cell Therapy in R/R DLBCL

August 9th 2021

Experts in lymphoma explain when and for which patients CAR T therapies are recommended in R/R DLBCL.

Newer Approvals for Previously Treated DLBCL

August 9th 2021

A panel of experts review the FDA approvals of loncastuximab tesirine and selinexor for the treatment of DLBCL in patients who have received at least 2 prior therapies.

DLBCL: Approaches to Treating Patients Ineligible for Transplant

August 2nd 2021

Key opinion leaders highlight treatment approaches for patients with DLBCL (diffuse large B-cell lymphoma) who are ineligible for transplant.

Data From the L-MIND Trial

August 2nd 2021

Greg Nowakowski, MD [Mayo Clinic, Rochester, Minnesota], reviews the data from the L-MIND trial of tafasitamab and lenalidomide for transplant-ineligible patients with R/R DLBCL (relapsed/refractory diffuse large B-cell lymphoma).

Recommendations for Second-Line Therapy in DLBCL

July 26th 2021

Key opinion leaders discuss recommended second-line treatment options for patients with DLBCL.

Managing Relapsed DLBCL

July 26th 2021

Cyrus Khan, MD, reviews the management of DLBCL after relapse on frontline therapy.

Outlook for CNS Lymphoma

July 19th 2021

David Rizzieri, MD, discusses new data from the ASCO 2021 Virtual Meeting regarding CNS lymphoma and treatment approaches in this setting.

DLBCL: Approaching CNS Prophylaxis

July 19th 2021

A panel of experts explain how they approach CNS prophylaxis in DLBCL.

Treatment Considerations in DLBCL

July 12th 2021

Loretta Nastoupil, MD, provides insight on treatment considerations after receiving molecular testing results in patients with newly diagnosed DLBCL.

Treating Newly Diagnosed Patients With DLBCL

July 12th 2021

Greg Nowakowski, MD, discusses considerations in treating a newly diagnosed patient with DLBCL.

Novel Therapies for R/R Follicular Lymphoma

April 19th 2021

A panel of hematologists/oncologists remark on the transformations occurring in relapsed/refractory follicular lymphoma as newer, novel therapies continue to emerge.

CAR T for R/R FL: Treatment Considerations

April 19th 2021

Factors that should be considered when evaluating patients with relapsed/refractory follicular lymphoma for CAR T-cell therapy.

CAR T-Cell Therapy for R/R Follicular Lymphoma

April 12th 2021

Implications for adding CAR T-cell therapy to the treatment armamentarium for relapsed/refractory follicular lymphoma in the near future.

ZUMA-5 in R/R Follicular Lymphoma

April 12th 2021

Caron A. Jacobson, MD, MMSc, of Dana-Farber Cancer Institute, comments on current data demonstrated by the ZUMA-5 trial in relapsed/refractory follicular lymphoma and the potential use of CAR T-cell therapy moving forward.

Treating Follicular Lymphoma With Early Progression

April 5th 2021

Approaches to sequencing therapy for patients with follicular lymphoma who experience progression of disease within 24 months (POD24).